Sodium phosphate, monobasic

Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Name
Sodium phosphate, monobasic
Accession Number
DB09449  (DB09127, DB11083, DB09524, DB09542, DB09468, DB11084, DB09482, DB09469, DB09525, DBSALT001969)
Type
Small Molecule
Groups
Approved
Description

Sodium phosphate is a saline laxative that is thought to work by increasing fluid in the small intestine. It usually results in a bowel movement after 30 minutes to 6 hours.

Structure
Thumb
Synonyms
  • Disodium hydrogen phosphate anhydrous
  • Monosodium dihydrogen monophosphate
  • Monosodium dihydrogen orthophosphate
  • Monosodium monophosphate
  • Monosodium phosphate, anhydrous
  • Phosphoric acid, monosodium salt, anhydrous
  • Sodium acid phosphate
  • Sodium biphosphate, anhydrous
  • Sodium dihydrogen phosphate, anhydrous
  • Sodium orthophosphate
  • Sodium orthophosphate monobasic
  • Sodium phosphate monobasic
  • Sodium phosphate monobasic (anhydrate)
  • Sodium phosphate monobasic (anhydrous)
  • Sodium phosphate, monobasic
  • Sodium phosphate, monobasic anhydrous
  • Sodium phosphate,monobasic
  • Sodium primary phosphate
External IDs
E-339(I) / INS NO.339(I) / INS-339(I)
Product Ingredients
IngredientUNIICASInChI Key
Sodium phosphate, monobasic, dihydrate5QWK66595613472-35-0VBJGJHBYWREJQD-UHFFFAOYSA-M
Sodium phosphate, monobasic, monohydrate593YOG76RN10049-21-5BBMHARZCALWXSL-UHFFFAOYSA-M
Active Moieties
NameKindUNIICASInChI Key
Phosphoric acidunknownE4GA8884NN7664-38-2NBIIXXVUZAFLBC-UHFFFAOYSA-N
Sodium cationionicLYR4M0NH3717341-25-2FKNQFGJONOIPTF-UHFFFAOYSA-N
Phosphate ionionicNK08V8K8HR14265-44-2NBIIXXVUZAFLBC-UHFFFAOYSA-K
Product Images
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Additive Formula 3Sodium phosphate, monobasic, monohydrate (0.28 g/100mL) + Adenine (0.03 g/100mL) + Citric acid monohydrate (0.042 g/100mL) + D-glucose monohydrate (1.1 g/100mL) + Sodium chloride (0.41 g/100mL) + Sodium citrate dihydrate (0.59 g/100mL)SolutionIntravenousTerumo Bct, Ltd2002-05-29Not applicableUs
Additive Formula 3Sodium phosphate, monobasic, monohydrate (0.28 g/100mL) + Adenine (0.03 g/100mL) + Citric acid monohydrate (0.042 g/100mL) + D-glucose monohydrate (1.1 g/100mL) + Sodium chloride (0.41 g/100mL) + Sodium citrate dihydrate (0.59 g/100mL)SolutionIntravenousTerumo Bct, Ltd2002-05-29Not applicableUs
Additive Formula 3Sodium phosphate, monobasic, monohydrate (0.28 g/100mL) + Adenine (0.03 g/100mL) + Citric acid monohydrate (0.042 g/100mL) + D-glucose monohydrate (1.1 g/100mL) + Sodium chloride (0.41 g/100mL) + Sodium citrate dihydrate (0.59 g/100mL)SolutionIntravenousTerumo Bct, Ltd2002-05-29Not applicableUs
Additive Solution Formula 3 As-3Sodium phosphate, monobasic, monohydrate (0.276 g) + Adenine (0.030 g) + Citric acid monohydrate (0.042 g) + Dextrose, unspecified form (1.10 g) + Sodium chloride (0.410 g) + Sodium citrate dihydrate (0.588 g)SolutionUnknownTerumo Bct, Inc.2013-05-31Not applicableCanada
ADSOL Red Cell Preservation Solution System in Plastic Container (PL 146 Plastic)Sodium phosphate, monobasic, monohydrate (155 mg/70mL) + Adenine (30 mg/110mL) + Citric acid (209 mg/70mL) + D-glucose monohydrate (1.78 g/70mL) + D-glucose monohydrate (2.42 g/110mL) + Mannitol (825 mg/110mL) + Sodium chloride (990 mg/110mL) + Sodium citrate dihydrate (1.84 g/70mL)KitIntravenousFenwal, Inc.2007-03-01Not applicableUs
ADSOL Red Cell Preservation Solution System in Plastic Container (PL 146 Plastic)Sodium phosphate, monobasic, monohydrate (155 mg/70mL) + Adenine (30 mg/110mL) + Citric acid (209 mg/70mL) + D-glucose monohydrate (1.78 g/70mL) + D-glucose monohydrate (2.42 g/110mL) + Mannitol (825 mg/110mL) + Sodium chloride (990 mg/110mL) + Sodium citrate dihydrate (1.84 g/70mL)KitIntravenousFenwal, Inc.2009-05-15Not applicableUs
ADSOL Red Cell Preservation Solution System in Plastic Container (PL 146 Plastic)Sodium phosphate, monobasic, monohydrate (155 mg/70mL) + Adenine (30 mg/110mL) + Citric acid (209 mg/70mL) + D-glucose monohydrate (1.78 g/70mL) + D-glucose monohydrate (2.42 g/110mL) + Mannitol (825 mg/110mL) + Sodium chloride (990 mg/110mL) + Sodium citrate dihydrate (1.84 g/70mL)KitIntravenousFenwal, Inc.2007-10-01Not applicableUs
ADSOL Red Cell Preservation Solution System in Plastic Container (PL 146 Plastic)Sodium phosphate, monobasic, monohydrate (155 mg/70mL) + Adenine (30 mg/110mL) + Citric acid (209 mg/70mL) + D-glucose monohydrate (1.78 g/70mL) + D-glucose monohydrate (2.42 g/110mL) + Mannitol (825 mg/110mL) + Sodium chloride (990 mg/110mL) + Sodium citrate dihydrate (1.84 g/70mL)KitIntravenousFenwal, Inc.2007-03-01Not applicableUs
ADSOL Red Cell Preservation Solution System in Plastic Container (PL 146 Plastic)Sodium phosphate, monobasic, monohydrate (155 mg/70mL) + Adenine (30 mg/110mL) + Citric acid (209 mg/70mL) + D-glucose monohydrate (1.78 g/70mL) + D-glucose monohydrate (2.42 g/110mL) + Mannitol (825 mg/110mL) + Sodium chloride (990 mg/110mL) + Sodium citrate dihydrate (1.84 g/70mL)KitIntravenousFenwal, Inc.2007-03-01Not applicableUs
ADSOL Red Cell Preservation Solution System in Plastic Container (PL 146 Plastic)Sodium phosphate, monobasic, monohydrate (140 mg/63mL) + Adenine (27 mg/100mL) + Citric acid (188 mg/63mL) + D-glucose monohydrate (1.61 g/63mL) + D-glucose monohydrate (2.2 g/100mL) + Mannitol (750 mg/100mL) + Sodium chloride (900 mg/100mL) + Sodium citrate dihydrate (1.66 g/63mL)KitIntravenousFenwal, Inc.2011-03-04Not applicableUs
Unapproved/Other Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Azuphen MbSodium phosphate, monobasic, monohydrate (40.8 mg/1) + Hyoscyamine sulfate dihydrate (0.12 mg/1) + Methenamine (120 mg/1) + Methylene blue trihydrate (10 mg/1) + Phenyl salicylate (36 mg/1)CapsuleOralBurel Pharmaceuticals, Llc2015-09-282016-11-01Us
DarpazSodium phosphate, monobasic (40.8 mg/1) + Hyoscyamine sulfate dihydrate (.12 mg/1) + Methenamine (81 mg/1) + Methylene blue trihydrate (10.8 mg/1) + Phenyl salicylate (32.4 mg/1)TabletOralRiver's Edge Pharmaceuticals, LLC2008-12-012011-05-31Us
Dibasic Sodium Phosphate, Monobasic Potassium Phosphate and Monobasic Sodium PhosphateSodium phosphate, monobasic, monohydrate (130 mg/1) + Monopotassium phosphate (155 mg/1) + Sodium phosphate, dibasic (852 mg/1)TabletOralRising Pharmaceuticals, Inc.2012-06-28Not applicableUs
Dibasic Sodium Phosphate, Monobasic Potassium Phosphate and Monobasic Sodium PhosphateSodium phosphate, monobasic, monohydrate (130 mg/1) + Monopotassium phosphate (155 mg/1) + Sodium phosphate, dibasic (852 mg/1)TabletOralCarilion Materials Management2012-06-28Not applicableUs64980 0104 01 nlmimage10 cc046643
Dibasic Sodium Phosphate, Monobasic Potassium Phosphate and Monobasic Sodium PhosphateSodium phosphate, monobasic, monohydrate (130 mg/1) + Monopotassium phosphate (155 mg/1) + Sodium phosphate, dibasic (852 mg/1)TabletOralKaiser Foundations Hospitals2014-07-07Not applicableUs
Dibasic Sodium Phosphate, Monobasic Potassium Phosphate and Monobasic Sodium PhosphateSodium phosphate, monobasic, monohydrate (130 mg/1) + Monopotassium phosphate (155 mg/1) + Sodium phosphate, dibasic (852 mg/1)TabletOralCardinal Health2012-06-282018-05-17Us55154 767620180907 15195 nnrmgf
Dibasic Sodium Phosphate, Monobasic Potassium Phosphate and Monobasic Sodium PhosphateSodium phosphate, monobasic, monohydrate (130 mg/1) + Monopotassium phosphate (155 mg/1) + Sodium phosphate, dibasic (852 mg/1)TabletOralAmerican Health Packaging2014-05-132020-06-30Us
Dibasic Sodium Phosphate, Monobasic Potassium Phosphate and Monobasic Sodium PhosphateSodium phosphate, monobasic, monohydrate (130 mg/1) + Monopotassium phosphate (155 mg/1) + Sodium phosphate, dibasic (852 mg/1)TabletOralAvera McKennan Hospital2015-03-112018-06-05Us69189 010420180907 15195 1028m42
Hyolev MbSodium phosphate, monobasic, monohydrate (40.8 mg/1) + Hyoscyamine sulfate dihydrate (0.12 mg/1) + Methenamine (81 mg/1) + Methylene blue trihydrate (10.8 mg/1) + Phenyl salicylate (32.4 mg/1)TabletOralBurel Pharmaceuticals, Llc2015-06-262016-11-01Us
Indiomin MbSodium phosphate, monobasic, monohydrate (40.8 mg/1) + Hyoscyamine sulfate dihydrate (0.12 mg/1) + Methenamine (120 mg/1) + Methylene blue trihydrate (10 mg/1)CapsuleOralBurel Pharmaceuticals, Llc2015-09-282016-10-24Us
Categories
UNII
KH7I04HPUU
CAS number
7558-80-7
Weight
Average: 119.977
Monoisotopic: 119.958839739
Chemical Formula
H2NaO4P
InChI Key
AJPJDKMHJJGVTQ-UHFFFAOYSA-M
InChI
InChI=1S/Na.H3O4P/c;1-5(2,3)4/h;(H3,1,2,3,4)/q+1;/p-1
IUPAC Name
sodium dihydrogen phosphate
SMILES
[Na+].OP(O)([O-])=O

Pharmacology

Indication

Used to treat constipation or to clean the bowel before a colonoscopy Label.

Associated Conditions
Associated Therapies
Pharmacodynamics

Sodium phosphate inceases fecal water content to increase mobility through the large intestine 1.

Mechanism of action

Sodium phosphate is thought to work by increasing the amount of solute present in the intestinal lumen thereby creating an osmotic gradient which draws water into the lumen 1.

Additional Data Available
Adverse Effects

Comprehensive structured data on known drug adverse effects with statistical prevalence. MedDRA and ICD10 ids are provided for adverse effect conditions and symptoms.

Learn more
Additional Data Available
Contraindications

Structured data covering drug contraindications. Each contraindication describes a scenario in which the drug is not to be used. Includes restrictions on co-administration, contraindicated populations, and more.

Learn more
Additional Data Available
Blackbox Warnings

Structured data representing warnings from the black box section of drug labels. These warnings cover important and dangerous risks, contraindications, or adverse effects.

Learn more
Absorption

Tmax for phosphate absorption with orally administered liquid sodium phosphate is 1-3h 3.

Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity

Intamuscular LD50 of 250mg/kg and oral LD50 of 8290 mg/kg reported in rats 7. Phosphate toxicity is likely due to the disturbance of other electrolytes when phosphate levels are high, producing symptoms including tetany, dehydration, hypotension, tachycardia, hyperpyrexia, cardiac arrest and coma 4. Risk of raising phosphate levels through use of sodium phosphate appears to be higher in smaller patients 3.

Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
2,5-Dimethoxy-4-ethylamphetamineThe serum concentration of 2,5-Dimethoxy-4-ethylamphetamine can be decreased when it is combined with Sodium phosphate, monobasic.
2,5-Dimethoxy-4-ethylthioamphetamineThe serum concentration of 2,5-Dimethoxy-4-ethylthioamphetamine can be decreased when it is combined with Sodium phosphate, monobasic.
4-Bromo-2,5-dimethoxyamphetamineThe serum concentration of 4-Bromo-2,5-dimethoxyamphetamine can be decreased when it is combined with Sodium phosphate, monobasic.
7-NitroindazoleThe therapeutic efficacy of 7-Nitroindazole can be decreased when used in combination with Sodium phosphate, monobasic.
AcebutololSodium phosphate, monobasic may increase the hyperkalemic activities of Acebutolol.
AceclofenacThe risk or severity of renal failure can be increased when Sodium phosphate, monobasic is combined with Aceclofenac.
AcemetacinThe risk or severity of renal failure can be increased when Sodium phosphate, monobasic is combined with Acemetacin.
AcetazolamideAcetazolamide may increase the nephrotoxic activities of Sodium phosphate, monobasic.
Acetylsalicylic acidThe risk or severity of renal failure can be increased when Sodium phosphate, monobasic is combined with Acetylsalicylic acid.
AclidiniumThe therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Aclidinium.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

References

General References
  1. Rex DK: Dosing considerations in the use of sodium phosphate bowel preparations for colonoscopy. Ann Pharmacother. 2007 Sep;41(9):1466-75. Epub 2007 Jul 24. [PubMed:17652123]
  2. Schanz S, Kruis W, Mickisch O, Kuppers B, Berg P, Frick B, Heiland G, Huppe D, Schenck B, Horstkotte H, Winkler A: Bowel Preparation for Colonoscopy with Sodium Phosphate Solution versus Polyethylene Glycol-Based Lavage: A Multicenter Trial. Diagn Ther Endosc. 2008;2008:713521. doi: 10.1155/2008/713521. [PubMed:18645612]
  3. Ehrenpreis ED: Increased serum phosphate levels and calcium fluxes are seen in smaller individuals after a single dose of sodium phosphate colon cleansing solution: a pharmacokinetic analysis. Aliment Pharmacol Ther. 2009 Jun 1;29(11):1202-11. doi: 10.1111/j.1365-2036.2009.03987.x. Epub 2009 Feb 27. [PubMed:19298584]
  4. Razzaque MS: Phosphate toxicity: new insights into an old problem. Clin Sci (Lond). 2011 Feb;120(3):91-7. doi: 10.1042/CS20100377. [PubMed:20958267]
  5. Biber J, Hernando N, Forster I: Phosphate transporters and their function. Annu Rev Physiol. 2013;75:535-50. doi: 10.1146/annurev-physiol-030212-183748. [PubMed:23398154]
  6. FDA Guide: Sodium Phosphate Tablet [Link]
  7. ChemIDPlus: Sodium Phosphate [Link]
External Links
PubChem Compound
23672064
PubChem Substance
347827853
ChemSpider
22626
ChEBI
37585
ChEMBL
CHEMBL1368
Wikipedia
Sodium_phosphates
FDA label
Download (359 KB)
MSDS
Download (84.7 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3CompletedNot AvailableColonoscopy1
3RecruitingTreatmentBowel preparation therapy1
3Unknown StatusNot AvailableMalignant Neoplasm of Colon1
4CompletedNot AvailableDry Eye1
4CompletedOtherSickle Cell Disorders1
4CompletedTreatmentColon Cleansing1
4CompletedTreatmentPsoriasis / Sleep Apnea, Obstructive1
4Not Yet RecruitingBasic ScienceHeart Defects,Congenital1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
SolutionUnknown
KitIntravenous
LiquidIntravenous
SolutionIntravenous
PasteDental
InjectionIntrathecal
LiquidIrrigation
LiquidIntravesical
Injection, solutionIntravenous
Tablet, coatedOral
TabletOral
CapsuleOral
LiquidOral
SolutionOral
SolutionExtracorporeal
EnemaRectal
SolutionRespiratory (inhalation)
Tablet, film coatedOral
Tablet, sugar coatedOral
Prices
Not Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US7687075No2010-03-302028-06-22Us
US7084130No2006-08-012021-11-29Us
Additional Data Available
  • Filed On
    Filed On

    The date on which a patent was filed with the relevant government.

    Learn more

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)Decomposes at 75MSDS
water solubility121 g/LMSDS
Predicted Properties
PropertyValueSource
logP-1ChemAxon
pKa (Strongest Acidic)1.8ChemAxon
Physiological Charge-2ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area80.59 Å2ChemAxon
Rotatable Bond Count0ChemAxon
Refractivity13.53 m3·mol-1ChemAxon
Polarizability5.53 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available

Taxonomy

Description
This compound belongs to the class of inorganic compounds known as alkali metal phosphates. These are inorganic compounds in which the largest oxoanion is phosphate, and in which the heaviest atom not in an oxoanion is an alkali metal.
Kingdom
Inorganic compounds
Super Class
Mixed metal/non-metal compounds
Class
Alkali metal oxoanionic compounds
Sub Class
Alkali metal phosphates
Direct Parent
Alkali metal phosphates
Alternative Parents
Inorganic sodium salts / Inorganic oxides
Substituents
Alkali metal phosphate / Inorganic sodium salt / Inorganic oxide / Inorganic salt
Molecular Framework
Not Available
External Descriptors
sodium phosphate (CHEBI:37585)

Transporters

Kind
Protein
Organism
Humans
Pharmacological action
No
Actions
Substrate
General Function
Not Available
Specific Function
Not Available
Gene Name
SLC20A1
Uniprot ID
Q8WUM9
Uniprot Name
Sodium-dependent phosphate transporter 1
Molecular Weight
73699.01 Da
References
  1. Biber J, Hernando N, Forster I: Phosphate transporters and their function. Annu Rev Physiol. 2013;75:535-50. doi: 10.1146/annurev-physiol-030212-183748. [PubMed:23398154]
Kind
Protein
Organism
Humans
Pharmacological action
No
Actions
Substrate
General Function
Virus receptor activity
Specific Function
Sodium-phosphate symporter which seems to play a fundamental housekeeping role in phosphate transport by absorbing phosphate from interstitial fluid for normal cellular functions such as cellular m...
Gene Name
SLC20A2
Uniprot ID
Q08357
Uniprot Name
Sodium-dependent phosphate transporter 2
Molecular Weight
70391.755 Da
References
  1. Biber J, Hernando N, Forster I: Phosphate transporters and their function. Annu Rev Physiol. 2013;75:535-50. doi: 10.1146/annurev-physiol-030212-183748. [PubMed:23398154]
Kind
Protein
Organism
Humans
Pharmacological action
No
Actions
Substrate
General Function
Sodium:phosphate symporter activity
Specific Function
Involved in actively transporting phosphate into cells via Na(+) cotransport in the renal brush border membrane. Probably mediates 70-80% of the apical influx.
Gene Name
SLC34A1
Uniprot ID
Q06495
Uniprot Name
Sodium-dependent phosphate transport protein 2A
Molecular Weight
68936.53 Da
References
  1. Biber J, Hernando N, Forster I: Phosphate transporters and their function. Annu Rev Physiol. 2013;75:535-50. doi: 10.1146/annurev-physiol-030212-183748. [PubMed:23398154]
Kind
Protein
Organism
Humans
Pharmacological action
No
Actions
Substrate
General Function
Sodium:phosphate symporter activity
Specific Function
May be involved in actively transporting phosphate into cells via Na(+) cotransport. It may be the main phosphate transport protein in the intestinal brush border membrane. May have a role in the s...
Gene Name
SLC34A2
Uniprot ID
O95436
Uniprot Name
Sodium-dependent phosphate transport protein 2B
Molecular Weight
75758.535 Da
References
  1. Biber J, Hernando N, Forster I: Phosphate transporters and their function. Annu Rev Physiol. 2013;75:535-50. doi: 10.1146/annurev-physiol-030212-183748. [PubMed:23398154]
Kind
Protein
Organism
Humans
Pharmacological action
No
Actions
Substrate
General Function
Sodium:phosphate symporter activity
Specific Function
May be involved in actively transporting phosphate into cells via Na(+) cotransport in the renal brush border membrane. Probably mediates 20-30% of the apical influx.
Gene Name
SLC34A3
Uniprot ID
Q8N130
Uniprot Name
Sodium-dependent phosphate transport protein 2C
Molecular Weight
63548.94 Da
References
  1. Kirchheiner J, Meineke I, Muller G, Roots I, Brockmoller J: Contributions of CYP2D6, CYP2C9 and CYP2C19 to the biotransformation of E- and Z-doxepin in healthy volunteers. Pharmacogenetics. 2002 Oct;12(7):571-80. [PubMed:12360109]

Drug created on November 30, 2015 12:10 / Updated on November 02, 2019 04:33